Pure Global AI
NCT06230588Recruiting

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQH3906 Capsules in Healthy Volunteers
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Psoriasis
Drug/Device/Intervention
TQH3906 capsule
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Funder
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Location
Chengdu, China
Timeline & enrollment
Phase
Phase 1
Start date
Feb 02, 2024
End date
Oct 01, 2024
Enrollment
76 participants
Primary outcome

Adverse events (AE),Serious Adverse Events (SAE),Treatment-emergent adverse events (TEAEs)

Summary

This study was divided into three parts: single and multiple dosing and food effect study,
 which were designed to evaluate the safety and tolerability of TQH3906 capsules administered
 in single or multiple dose escalation in healthy adult subjects.

ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06230588
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06230588 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 76 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.